Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07455331

Flash Radiotherapy for Skin Cancer

Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Participants With Localized Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Jules Bordet Institute · Academic / Other
Sex
All
Age
60 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous Squamous Cell Carcinoma (cSCC) and Basal Cell Carcinoma (BCC). FLASH therapy can deliver the irradiation dose within milliseconds instead of the minutes commonly required in conventional radiotherapy, with the aim of providing a curative dose while minimizing side effects on healthy tissue. This is a phase II selection and monocentric clinical investigation with a 1 to 1 randomization. This clinical investigation will include approximately 60 participants aged ≥ 60 years old with one or more localized cSCC and BCC who either cannot undergo surgery or decline surgical resection. The study design is the following: * On day 1, either a single dose FLASH radiotherapy (22 Gy) will be delivered or a single dose conventional radiotherapy (22 Gy) will be delivered to the selected localized cSCC or BCC lesion(s) (up to maximum 3 per participant; all lesions distant of at least 4 cm from one-another). * The surveillance period will be of 6 weeks post irradiation. * Follow-up visits will take place at 3, 6, and 12 months post-treatment.

Conditions

Interventions

TypeNameDescription
RADIATIONFLASH radiotherapyFLASH therapy is delivered almost instantaneously (in milliseconds), as opposed to conventional radiotherapy, which is delivering the dose in minutes.
RADIATIONConventional radiotherapyStandard of Care

Timeline

Start date
2026-03-23
Primary completion
2029-12-23
Completion
2030-12-23
First posted
2026-03-06
Last updated
2026-03-06

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT07455331. Inclusion in this directory is not an endorsement.